Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-07-18Clinical Trial Update: A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy [Phase 3]
Phase 3 trial evaluating abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer after failure of docetaxel-b…
-
FDA approval · 2019-07-10FDA Approved: ABIRATERONE — Original Application (BluePoint Laboratories)
FDA approved BluePoint Laboratories' original application for ABIRATERONE acetate as a generic version for prostate cancer (metastatic castr…
-
CLINICAL_TRIALS trial_result · 2019-07-05Clinical Trial Update: Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer [Phase 2]
Phase 2 clinical trial evaluating the effect of food on the pharmacokinetics of abiraterone acetate in patients with castration-resistant pr…
-
CLINICAL_TRIALS trial_result · 2019-06-21Clinical Trial Update: Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide [Phase 2]
Phase 2 trial comparing cabazitaxel versus switch to alternative AR-targeted therapy (enzalutamide or abiraterone) in metastatic castration-…
-
FDA approval · 2019-06-03FDA Approved: ZYTIGA — Supplemental Application (Janssen Biotech, Inc.)
FDA approves a supplemental application for ZYTIGA (abiraterone acetate) from Janssen Biotech, Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-03-19Clinical Trial Update: Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC) [Phase 2]
Phase 2 trial update for Dovitinib and Abiraterone Acetate in metastatic castration-resistant prostate cancer has been terminated with resul…
-
CLINICAL_TRIALS trial_result · 2019-03-05Clinical Trial Update: Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms [Phase 3]
Phase 3 trial comparing Radium-223 dichloride with Abiraterone acetate versus placebo with Abiraterone acetate in chemo-naïve metastatic cas…
-
FDA approval · 2019-02-25FDA Approved: ABIRATERONE ACETATE — Original Application (Rising Pharma Holdings, Inc.)
FDA approved the original application for a generic abiraterone acetate, manufactured by Rising Pharma Holdings, expanding access for treatm…
-
CLINICAL_TRIALS trial_result · 2019-02-15Clinical Trial Update: A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen [Phase 1]
This Phase 1 trial evaluated alisertib in combination with standard docetaxel in patients with advanced solid tumors, including castration-r…
-
CLINICAL_TRIALS trial_result · 2019-02-15Clinical Trial Update: OGX-427 in Castration Resistant Prostate Cancer Patients [Phase 2]
A Phase 2 clinical trial of OGX-427 (apatorsen) in castration-resistant prostate cancer has completed.
-
CLINICAL_TRIALS trial_result · 2019-02-05Clinical Trial Update: A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients [Phase 2]
A Phase 2 trial assessed the safety and tolerability of combining enzalutamide with abiraterone acetate in bone-metastatic castration-resist…
-
CLINICAL_TRIALS trial_result · 2019-02-05Clinical Trial Update: BKM120+Abiraterone Acetate for Metastatic CRPC [Phase 1]
Phase 1 study of Buparlisib (BKM120) in combination with Abiraterone acetate for metastatic castration-resistant prostate cancer was termina…
-
CLINICAL_TRIALS trial_result · 2019-02-01Clinical Trial Update: A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer [Phase 1, Phase 2]
This document reports the completion of a Phase 1/2 clinical trial evaluating the once-daily oral drug VT-464 in patients with castration-re…
-
CLINICAL_TRIALS trial_result · 2019-02-01Clinical Trial Update: A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer [Phase 2]
Innocrin's Phase 2 study evaluating the oral agent VT-464 in castration-resistant prostate cancer has completed.
-
CLINICAL_TRIALS trial_result · 2019-02-01Clinical Trial Update: Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone. [Phase 2]
Phase 2 clinical trial update evaluating seviteronel in patients with castration-resistant prostate cancer progressing on enzalutamide or ab…
-
FDA approval · 2019-01-07FDA Approved: ABIRATERONE ACETATE — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved Amneal Pharmaceuticals NY LLC's original application for a generic abiraterone acetate product, expanding access to treatment f…
-
CLINICAL_TRIALS trial_result · 2018-12-19Clinical Trial Update: Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment [Phase 2]
Phase 2 trial investigating carfilzomib in metastatic castration-resistant prostate cancer has completed with results posted.
-
CLINICAL_TRIALS research · 2018-12-11Clinical Trial Update: CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]
Phase 2 clinical trial update evaluating CYT107 following Provenge treatment in metastatic castration-resistant prostate cancer; results pos…
-
CLINICAL_TRIALS trial_result · 2018-12-04Clinical Trial Update: Cabozantinib in Men With Castration-Resistant Prostate Cancer [Phase 2]
Phase 2 trial investigating cabozantinib in men with castration-resistant prostate cancer has been terminated; results posted.
-
FDA approval · 2018-10-31FDA Approved: ABIRATERONE ACETATE — Original Application (Apotex Corp.)
FDA approved Abiraterone acetate (generic) from Apotex Corp. under an original ANDA, enabling a generic version of the cancer drug for metas…
-
FDA approval · 2018-10-31FDA Approved: ABIRATERONE ACETATE — Original Application (Mylan Pharmaceuticals Inc.)
The FDA approved Mylan's original application for Abiraterone acetate, enabling a generic version of the cancer drug used for metastatic cas…
-
FDA approval · 2018-10-31FDA Approved: ABIRATERONE — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approves Hikma Pharmaceuticals USA Inc.'s original application for a generic abiraterone acetate product (ABIRATERONE) for the treatment…
-
CLINICAL_TRIALS trial_result · 2018-10-18Clinical Trial Update: OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone [Phase 2]
Phase 2 trial update for OGX-427 in metastatic castration-resistant prostate cancer with PSA progression on abiraterone; study status termin…
-
CLINICAL_TRIALS trial_result · 2018-10-11Clinical Trial Update: A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer [Phase 2]
Phase 2 trial evaluating a combination of bevacizumab, lenalidomide, docetaxel, and prednisone (ART-P) for metastatic castration-resistant p…
-
CLINICAL_TRIALS trial_result · 2018-10-09Clinical Trial Update: Selective Treatment According to Molecular Subtype of Prostate Cancer [Phase 2]
A Phase 2 clinical trial update exploring selective treatment based on molecular subtype in prostate cancer, including castration-resistant …